China Resources Sanjiu Medical & Pharmaceutical Toekomstige groei
Future criteriumcontroles 1/6
China Resources Sanjiu Medical & Pharmaceutical zal naar verwachting groeien in winst en omzet met respectievelijk 11.2% en 9.8% per jaar. De winst per aandeel zal naar verwachting groeien met 11.5% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 17.9% zijn.
Belangrijke informatie
11.2%
Groei van de winst
11.5%
Groei van de winst per aandeel
Pharmaceuticals winstgroei | 19.0% |
Inkomstengroei | 9.8% |
Toekomstig rendement op eigen vermogen | 17.9% |
Dekking van analisten | Good |
Laatst bijgewerkt | 18 Nov 2024 |
Recente toekomstige groei-updates
Analysts Are Updating Their China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (SZSE:000999) Estimates After Its Second-Quarter Results
Aug 26China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Apr 23Recent updates
Little Excitement Around China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.'s (SZSE:000999) Earnings
Nov 18Analysts Are Updating Their China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (SZSE:000999) Estimates After Its Second-Quarter Results
Aug 26Does China Resources Sanjiu Medical & Pharmaceutical (SZSE:000999) Have A Healthy Balance Sheet?
Aug 09Investors Aren't Buying China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.'s (SZSE:000999) Earnings
Jul 12China Resources Sanjiu Medical & Pharmaceutical (SZSE:000999) Is Increasing Its Dividend To CN¥1.50
Jun 09China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Apr 23An Intrinsic Calculation For China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (SZSE:000999) Suggests It's 50% Undervalued
Apr 16Investors Aren't Buying China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.'s (SZSE:000999) Earnings
Mar 20Do China Resources Sanjiu Medical & Pharmaceutical's (SZSE:000999) Earnings Warrant Your Attention?
Feb 28Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
12/31/2026 | 33,892 | 4,363 | 4,507 | 5,747 | 12 |
12/31/2025 | 31,142 | 3,865 | 3,449 | 4,642 | 14 |
12/31/2024 | 26,746 | 3,320 | 2,599 | 3,306 | 7 |
9/30/2024 | 25,871 | 3,410 | 3,575 | 4,346 | N/A |
6/30/2024 | 25,699 | 3,374 | 3,995 | 4,783 | N/A |
3/31/2024 | 25,681 | 3,066 | 3,897 | 4,677 | N/A |
12/31/2023 | 24,739 | 2,853 | 3,335 | 4,192 | N/A |
9/30/2023 | 24,577 | 2,899 | 3,068 | 4,039 | N/A |
6/30/2023 | 22,825 | 2,893 | 1,854 | 2,876 | N/A |
3/31/2023 | 20,182 | 2,759 | 1,856 | 2,858 | N/A |
1/1/2023 | 18,079 | 2,449 | 2,055 | 3,006 | N/A |
9/30/2022 | 16,393 | 2,251 | 1,599 | 2,448 | N/A |
6/30/2022 | 16,081 | 2,112 | 1,919 | 2,734 | N/A |
3/31/2022 | 15,715 | 2,253 | 1,254 | 2,055 | N/A |
1/1/2022 | 15,544 | 2,055 | 1,012 | 1,885 | N/A |
9/30/2021 | 15,586 | 1,773 | 1,299 | 2,133 | N/A |
6/30/2021 | 15,623 | 1,919 | 1,489 | 2,213 | N/A |
3/31/2021 | 14,556 | 1,717 | 1,112 | 1,857 | N/A |
12/31/2020 | 13,637 | 1,597 | 1,602 | 2,224 | N/A |
9/30/2020 | 13,920 | 1,710 | 1,346 | 1,976 | N/A |
6/30/2020 | 13,505 | 1,431 | 1,203 | 1,828 | N/A |
3/31/2020 | 14,473 | 1,455 | 1,741 | 2,263 | N/A |
12/31/2019 | 14,794 | 2,099 | 1,411 | 1,949 | N/A |
9/30/2019 | 14,171 | 2,289 | 1,447 | 1,906 | N/A |
6/30/2019 | 14,122 | 2,328 | 1,517 | 2,012 | N/A |
3/31/2019 | 13,530 | 2,176 | 1,396 | 2,009 | N/A |
12/31/2018 | 13,428 | 1,432 | 1,311 | 1,911 | N/A |
9/30/2018 | 13,080 | 1,455 | 1,358 | 1,943 | N/A |
6/30/2018 | 12,594 | 1,387 | N/A | 1,906 | N/A |
3/31/2018 | 12,043 | 1,350 | N/A | 1,697 | N/A |
12/31/2017 | 11,120 | 1,302 | N/A | 1,599 | N/A |
9/30/2017 | 10,301 | 1,288 | N/A | 1,577 | N/A |
6/30/2017 | 9,699 | 1,303 | N/A | 1,459 | N/A |
3/31/2017 | 9,307 | 1,260 | N/A | 1,347 | N/A |
12/31/2016 | 8,982 | 1,198 | N/A | 1,392 | N/A |
9/30/2016 | 8,553 | 1,290 | N/A | 1,335 | N/A |
6/30/2016 | 8,485 | 1,258 | N/A | 1,320 | N/A |
3/31/2016 | 8,149 | 1,223 | N/A | 1,341 | N/A |
12/31/2015 | 7,900 | 1,249 | N/A | 1,260 | N/A |
9/30/2015 | 7,709 | 1,160 | N/A | 1,338 | N/A |
6/30/2015 | 7,475 | 1,107 | N/A | 1,330 | N/A |
3/31/2015 | 7,412 | 1,086 | N/A | 1,213 | N/A |
12/31/2014 | 7,277 | 1,036 | N/A | 1,184 | N/A |
9/30/2014 | 6,770 | 938 | N/A | 1,105 | N/A |
6/30/2014 | 6,959 | 1,064 | N/A | 1,152 | N/A |
3/31/2014 | 7,196 | 1,058 | N/A | 1,177 | N/A |
12/31/2013 | 7,293 | 1,109 | N/A | 1,345 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachte winstgroei 000999 ( 11.2% per jaar) ligt boven de spaarquote ( 2.8% ).
Winst versus markt: De winst van 000999 ( 11.2% per jaar) zal naar verwachting langzamer groeien dan de markt CN ( 26.2% per jaar).
Hoge groeiwinsten: De winst van 000999 zal naar verwachting groeien, maar niet aanzienlijk.
Omzet versus markt: De omzet van 000999 ( 9.8% per jaar) zal naar verwachting langzamer groeien dan de markt CN ( 13.8% per jaar).
Hoge groei-inkomsten: De omzet van 000999 ( 9.8% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Het rendement op eigen vermogen 000999 zal naar verwachting over 3 jaar laag zijn ( 17.9 %).